Group 2 innate lymphoid cells boost CD8⁺ T-cell activation in anti-tumor immune responses

References

• Gurram RK, Zhu J. Orchestration between ILC2s and Th2 cells in shaping type 2 immune responses. Cell Mol Immunol. 2019;16(3):225–13. doi:10.1038/s41423-019-0210-8.
   PubMed Web of Science ®Google Scholar
• Mjösberg J, Bernink J, Golebski K, Karrich J, Peters C, Blom B, Te Velde A, Fokkens W, van Drunen C, Spits H, et al. The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity. 2012;37(4):649–659. doi: 10.1016/j.immuni.2012.08.015.
   PubMed Web of Science ®Google Scholar
• Ferreira ACF, Szeto ACH, Heycock MWD, Clark PA, Walker JA, Crisp A, Barlow JL, Kitching S, Lim A, Gogoi M, et al. RORα is a critical checkpoint for T cell and ILC2 commitment in the embryonic thymus. Nat Immunol. 2021;22(2):166–178. doi: 10.1038/s41590-020-00833-w.
   PubMed Web of Science ®Google Scholar
• Eberl G, Colonna M, Di Santo JP, McKenzie AN. Innate lymphoid cells. Innate lymphoid cells: a new paradigm in immunology. Sci. 2015;348(6237):aaa6566. doi:10.1126/science.aaa6566.
   PubMed Web of Science ®Google Scholar
• Oliphant CJ, Hwang Y, Walker J, Salimi M, Wong S, Brewer J, Englezakis A, Barlow J, Hams E, Scanlon S, et al. MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion. Immunity. 2014;41(2):283–295. doi: 10.1016/j.immuni.2014.06.016.
   PubMed Web of Science ®Google Scholar
• Ercolano G, Falquet M, Vanoni G, Trabanelli S, Jandus C. Ilc2s: New actors in tumor immunity. Front Immunol. 2019;10:2801. doi:10.3389/fimmu.2019.02801.
   PubMed Web of Science ®Google Scholar
• Spits H, Mjösberg J. Heterogeneity of type 2 innate lymphoid cells. Nat Rev Immunol. 2022;22(11):1–12. doi:10.1038/s41577-022-00704-5.
   PubMed Web of Science ®Google Scholar
• Trabanelli S, Curti A, Lecciso M, Salome B, Riether C, Ochsenbein A, Romero P, Jandus C. CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis. Haematologica. 2015;100(7):e257–260. doi:10.3324/haematol.2014.119602.
   PubMed Web of Science ®Google Scholar
• Chevalier MF, Trabanelli S, Racle J, Salomé B, Cesson V, Gharbi D, Bohner P, Domingos-Pereira S, Dartiguenave F, Fritschi A-S, et al. ILC2-modulated T cell–to-MDSC balance is associated with bladder cancer recurrence. J Clin Invest. 2017;127(8):2916–2929. doi: 10.1172/JCI89717.
   PubMed Web of Science ®Google Scholar
• Trabanelli S, Chevalier MF, Martinez-Usatorre A, Gomez-Cadena A, Salomé B, Lecciso M, Salvestrini V, Verdeil G, Racle J, Papayannidis C, et al. Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nat Commun. 2017;8(1):593. doi: 10.1038/s41467-017-00678-2.
   PubMed Web of Science ®Google Scholar
• Jacquelot N, Seillet C, Wang M, Pizzolla A, Liao Y, Hediyeh-Zadeh S, Grisaru-Tal S, Louis C, Huang Q, Schreuder J, et al. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nat Immunol. 2021;22(7):851–864. doi: 10.1038/s41590-021-00943-z.
   PubMed Web of Science ®Google Scholar
• Moral JA, Leung J, Rojas LA, Ruan J, Zhao J, Sethna Z, Ramnarain A, Gasmi B, Gururajan M, Redmond D, et al. Ilc2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature. 2020;579(7797):130–135. doi: 10.1038/s41586-020-2015-4.
   PubMed Web of Science ®Google Scholar
• Howard E, Hurrell BP, Helou DG, Quach C, Painter JD, Shafiei-Jahani P, Fung M, Gill PS, Soroosh P, Sharpe AH, et al. PD-1 blockade on tumor microenvironment-resident ILC2s promotes TNF-α production and restricts progression of metastatic melanoma. Front Immunol. 2021;12:733136. doi:10.3389/fimmu.2021.733136.
   PubMed Web of Science ®Google Scholar
• Wan J, Wu Y, Huang L, Tian Y, Ji X, Abdelaziz MH, Cai W, Dineshkumar K, Lei Y, Yao S, et al. ILC2-derived IL-9 inhibits colorectal cancer progression by activating CD8(+) T cells. Cancer Lett. 2021;502:34–43. doi:10.1016/j.canlet.2021.01.002.
   PubMed Web of Science ®Google Scholar
• Sonnenberg GF, Hepworth MR. Functional interactions between innate lymphoid cells and adaptive immunity. Nat Rev Immunol. 2019;19(10):599–613. doi:10.1038/s41577-019-0194-8.
   PubMed Web of Science ®Google Scholar
• Pelly VS, Kannan Y, Coomes SM, Entwistle LJ, Rückerl D, Seddon B, MacDonald AS, McKenzie A, Wilson MS. IL-4-producing ILC2s are required for the differentiation of T(H)2 cells following Heligmosomoides polygyrus infection. Mucosal Immunol. 2016;9(6):1407–1417. doi:10.1038/mi.2016.4.
   PubMed Web of Science ®Google Scholar
• Noval Rivas M, Burton OT, Oettgen HC, Chatila T. IL-4 production by group 2 innate lymphoid cells promotes food allergy by blocking regulatory T-cell function. J Allergy Clin Immunol. 2016;138(3):801–811.e809. doi:10.1016/j.jaci.2016.02.030.
   PubMed Web of Science ®Google Scholar
• Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, Furusawa J-I, Ohtani M, Fujii H, Koyasu S, et al. Innate production of T(H)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature. 2010;463(7280):540–544. doi: 10.1038/nature08636.
   PubMed Web of Science ®Google Scholar
• Jackson-Jones LH, Duncan SM, Magalhaes MS, Campbell SM, Maizels RM, McSorley HJ, Allen JE, Bénézech C. Fat-associated lymphoid clusters control local IgM secretion during pleural infection and lung inflammation. Nat Commun. 2016;7(1):12651. doi:10.1038/ncomms12651.
   PubMedGoogle Scholar
• Molofsky AB, Van Gool F, Liang H-E, Van Dyken S, Nussbaum J, Lee J, Bluestone J, Locksley R. Interleukin-33 and interferon-γ counter-regulate group 2 innate lymphoid cell activation during immune perturbation. Immunity. 2015;43(1):161–174. doi:10.1016/j.immuni.2015.05.019.
   PubMed Web of Science ®Google Scholar
• Webb GJ, Hirschfield GM, Lane PJ. OX40, OX40L and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol. 2016;50(3):312–332. doi:10.1007/s12016-015-8498-3.
   PubMed Web of Science ®Google Scholar
• Hardman CS, Chen Y-L, Salimi M, Jarrett R, Johnson D, Järvinen VJ, Owens RJ, Repapi E, Cousins DJ, Barlow JL, et al. Cd1a presentation of endogenous antigens by group 2 innate lymphoid cells. Sci Immunol. 2017;2(18). doi:10.1126/sciimmunol.aan5918.
   PubMed Web of Science ®Google Scholar
• Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 1994;12(1):337–365. doi:10.1146/annurev.iy.12.040194.002005.
   PubMedGoogle Scholar
• Anderson CK, Brossay L. The role of MHC class Ib-restricted T cells during infection. Immunogenetics. 2016;68(8):677–691. doi:10.1007/s00251-016-0932-z.
   PubMed Web of Science ®Google Scholar
• Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–242. doi:10.1038/nri3405.
   PubMed Web of Science ®Google Scholar
• Bürdek M, Spranger S, Wilde S, Frankenberger B, Schendel DJ, Geiger C. Three-day dendritic cells for vaccine development: antigen uptake, processing and presentation. J Transl Med. 2010;8(1):90. doi:10.1186/1479-5876-8-90.
   PubMedGoogle Scholar
• Liu L, Ye TH, Han YP, Song H, Zhang YK, Xia Y, Wang NY, Xiong Y, Song XJ, Zhu YX, et al. Reductions in myeloid-derived suppressor cells and lung metastases using AZD4547 treatment of a metastatic murine breast tumor model. Cell Physiol Biochem. 2014;33(3):633–645. doi: 10.1159/000358640.
   PubMedGoogle Scholar
• Okuyama Y, Okajima A, Sakamoto N, Hashimoto A, Tanabe R, Kawajiri A, Kawabe T, Ishii N. IL-33-ILC2 axis promotes anti-tumor CD8(+) T cell responses via OX40 signaling. Biochem Biophys Res Commun. 2022;637:9–16. doi:10.1016/j.bbrc.2022.11.006.
   PubMed Web of Science ®Google Scholar
• Huang MN, Nicholson LT, Batich KA, Swartz AM, Kopin D, Wellford S, Prabhakar VK, Woroniecka K, Nair SK, Fecci PE, et al. Antigen-loaded monocyte administration induces potent therapeutic antitumor T cell responses. J Clin Invest. 2020;130(2):774–788. doi: 10.1172/JCI128267.
   PubMed Web of Science ®Google Scholar
• Filley AC, Dey M. Dendritic cell based vaccination strategy: an evolving paradigm. J Neurooncol. 2017;133(2):223–235. doi:10.1007/s11060-017-2446-4.
   PubMed Web of Science ®Google Scholar
• Lehmann FM, von Burg N, Ivanek R, Teufel C, Horvath E, Peter A, Turchinovich G, Staehli D, Eichlisberger T, Gomez de Agüero M, et al. Microbiota-induced tissue signals regulate ILC3-mediated antigen presentation. Nat Commun. 2020;11(1):1794. doi: 10.1038/s41467-020-15612-2.
   PubMed Web of Science ®Google Scholar
• Grigg JB, Shanmugavadivu A, Regen T, Parkhurst CN, Ahmed A, Joseph AM, Mazzucco M, Gronke K, Diefenbach A, Eberl G, et al. Antigen-presenting innate lymphoid cells orchestrate neuroinflammation. Nature. 2021;600(7890):707–712. doi: 10.1038/s41586-021-04136-4.
   PubMed Web of Science ®Google Scholar
• Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, Kaisho T, Bogunovic D, Bhardwaj N, Krummel MF, et al. Critical role for CD103(+)/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell. 2016;30(2):324–336. doi: 10.1016/j.ccell.2016.06.003.
   PubMed Web of Science ®Google Scholar
• Nouri-Shirazi M, Banchereau J, Bell D, Burkeholder S, Kraus ET, Davoust J, Palucka KA. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol ( Baltimore, Md. : 1950). 2000;165(7):3797–3803. doi:10.4049/jimmunol.165.7.3797.
   PubMed Web of Science ®Google Scholar